These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1886533)

  • 41. Non-conventional growth hormone therapy in Turner syndrome: the United States experience.
    Rosenfeld RG
    Horm Res; 1990; 33(2-4):137-40; discussion 140-2. PubMed ID: 2210618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age.
    Stahnke N; Keller E; Landy H;
    J Pediatr Endocrinol Metab; 2002 Feb; 15(2):129-38. PubMed ID: 11874177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anabolic steroids in girls with Turner's syndrome.
    Joss EE
    Acta Paediatr Scand Suppl; 1988; 343():38-42. PubMed ID: 3057807
    [No Abstract]   [Full Text] [Related]  

  • 44. Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both.
    Wilson DM; Frane JW; Sherman B; Johanson AJ; Hintz RL; Rosenfeld RG
    J Pediatr; 1988 Feb; 112(2):210-7. PubMed ID: 3276862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term treatment with growth hormone has no persisting effect on lipoprotein(a) in patients with Turner's syndrome.
    Querfeld U; Döpper S; Gradehand A; Kiencke P; Wahn F; Zeisel HJ
    J Clin Endocrinol Metab; 1999 Mar; 84(3):967-70. PubMed ID: 10084580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of recombinant human growth hormone therapy on bone and clinical parameters in girls with Turner's syndrome. The Spanish Collaborative Group.
    Ferrández A; Mayayo E; Arnal JM; García C; Buñuel C; Lasarte JJ; Anton R; Puyuelo P
    Acta Paediatr Scand Suppl; 1989; 356():87-91; discussion 92. PubMed ID: 2816362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comments on 'Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome' by Zeger et al., pp. 39-47, this issue.
    Menke LA; Sas TC; Wit JM
    Horm Res Paediatr; 2011; 75(1):47-8. PubMed ID: 21051854
    [No Abstract]   [Full Text] [Related]  

  • 48. [Turner's syndrome: a revolution].
    Rochiccioli P; Tauber MT
    Arch Fr Pediatr; 1992 Mar; 49(3):153-5. PubMed ID: 1610268
    [No Abstract]   [Full Text] [Related]  

  • 49. Influence of hormonal therapy on growth rate and bone age progression in patients with Turner syndrome.
    Gawlik A; Gawlik T; Koehler B; Malecka-Tendera E; Augustyn M; Woska W
    Endokrynol Pol; 2005; 56(2):136-44. PubMed ID: 16335681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of oxandrolone on body proportions and body composition in growth hormone-treated girls with Turner syndrome.
    Menke LA; Sas TC; Zandwijken GR; de Ridder MA; Stijnen T; de Muinck Keizer-Schrama SM; Otten BJ; Wit JM
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):212-9. PubMed ID: 20105186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of short stature and delayed adolescence.
    Wilson DM; Rosenfeld RG
    Pediatr Clin North Am; 1987 Aug; 34(4):865-79. PubMed ID: 3302896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Growth promotion and Turner-specific bone age after therapy with growth hormone and in combination with oxandrolone: when should therapy be started in Turner syndrome?
    Joss EE; Mullis PE; Werder EA; Partsch CJ; Sippell WG
    Horm Res; 1997; 47(3):102-9. PubMed ID: 9050948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Turner's syndrome is not what it was in the past].
    Pierson M; Leheup B
    Arch Fr Pediatr; 1992 Mar; 49(3):149-52. PubMed ID: 1376983
    [No Abstract]   [Full Text] [Related]  

  • 54. What is the value of growth hormone treatment in short children with specified syndrome? Turner's syndrome, osteochondrodysplasias, Prader-Willi syndrome, Noonan syndrome.
    Nilsson KO
    Acta Paediatr Scand Suppl; 1989; 362():61-8. PubMed ID: 2485602
    [No Abstract]   [Full Text] [Related]  

  • 55. Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol.
    Massarano AA; Brook CG; Hindmarsh PC; Pringle PJ; Teale JD; Stanhope R; Preece MA
    Arch Dis Child; 1989 Apr; 64(4):587-92. PubMed ID: 2751332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term results of growth hormone therapy in Turner syndrome.
    Bramswig JH
    Endocrine; 2001 Jun; 15(1):5-13. PubMed ID: 11572325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Turner's syndrome: a paediatric perspective.
    Sas TC; de Muinck Keizer-Schrama SM;
    Horm Res; 2001; 56 Suppl 1():38-43. PubMed ID: 11786684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oxandrolone increases final height in Turner syndrome.
    Crock P; Werther GA; Wettenhall HN
    J Paediatr Child Health; 1990 Aug; 26(4):221-4. PubMed ID: 2257185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experience in management of diminished growth in adolescent Turner's syndrome patients.
    Tuschy U
    Padiatr Grenzgeb; 1992; 31(2):123-30. PubMed ID: 1305284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Demography, auxology and response to recombinant human growth hormone treatment in girls with Turner's syndrome in the Kabi Pharmacia International Growth Study. International Board of the Kabi Pharmacia International Growth Study.
    Price DA; Albertsson-Wikland K
    Acta Paediatr Suppl; 1993 Sep; 82 Suppl 391():69-74. PubMed ID: 8219480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.